Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences has completed its acquisition of Flexion Therapeutics, enhancing its offerings in non-opioid pain management. This strategic move incorporates ZILRETTA, a patented treatment for osteoarthritis knee pain, into Pacira's portfolio, allowing earlier intervention for patients. The acquisition is expected to diversify revenue streams and enhance cash flows substantially. CEO David Stack emphasized the significance of this deal in evolving pain management and reducing opioid reliance.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 11:20 AM GMT. Live audio of the event can be accessed through the company’s website, with a replay available for two weeks after. Pacira is a leader in non-opioid pain management solutions, highlighted by its long-acting local analgesic, EXPAREL, launched in April 2012. The company aims to reduce opioid reliance through innovative therapies and technologies.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for October 2021, noting that EXPAREL achieved sales of $42.5 million, a 4.4% increase from $40.7 million in October 2020. Average daily sales for EXPAREL rose to 109% compared to last year. Sales of iovera° were $1.2 million, up from $1.0 million in the same period. CEO Dave Stack expressed confidence in strong growth ahead, citing improved market conditions for elective surgeries. The company also plans to integrate ZILRETTA post-acquisition of Flexion Therapeutics, aiming for annual growth in the high teens and over 50% operating margins.
Pacira BioSciences (Nasdaq: PCRX) has filed a lawsuit against eVenus Pharmaceutical Laboratories for patent infringement related to EXPAREL (bupivacaine liposome injectable suspension), protecting U.S. Patent Number 11,033,495, which expires on January 22, 2041. The lawsuit triggers a 30-month stay on eVenus’ ANDA approval under the Hatch Waxman Act. This marks a significant step in Pacira's patent strategy, as the company aims to defend its intellectual property against potential generic competition.
Pacira BioSciences (Nasdaq: PCRX) reported third quarter 2021 financial results, achieving total revenues of $127.7 million, compared to $117.5 million in Q3 2020. The company recorded a GAAP net income of $17.7 million ($0.40 per share) and adjusted EBITDA of $48.1 million, up from $34.2 million a year prior. The positive trajectory is bolstered by strong EXPAREL sales, reaching $121.9 million. A proposed acquisition of Flexion Therapeutics aims to enhance growth efforts. Pacira's financial outlook remains bullish while navigating ongoing challenges from the COVID-19 pandemic.
Pacira BioSciences (Nasdaq: PCRX) has received Notice of Allowance from the USPTO for a U.S. Patent Application related to the chemical composition of EXPAREL (bupivacaine liposome injectable suspension) and a novel manufacturing process. Upon issuance, these patents will be eligible for listing in the FDA Orange Book, extending patent protection until January 22, 2041. This move enhances the company's intellectual property strategy, securing barriers against competition. CEO Dave Stack emphasized confidence in EXPAREL's market leadership across various medical procedures.
Pacira BioSciences, Inc. (NASDAQ:PCRX) is set to release its third quarter financial results on November 3, 2021, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can join the call by dialing the provided numbers or accessing the webcast via the Pacira investor website. Notably, Pacira emphasizes its leadership in non-opioid pain management, particularly with its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia system, highlighting its commitment to improving patient outcomes.
Pacira BioSciences (Nasdaq: PCRX) has announced its acquisition of Flexion Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) worth up to $8.00 per share, subject to certain milestones. This acquisition adds ZILRETTA, a non-opioid therapy for osteoarthritis knee pain, to Pacira's portfolio, enhancing its commitment to non-opioid pain management. The deal is expected to be accretive to earnings in 2022 and provides significant synergies. Pacira plans to fund the transaction from existing cash resources and expects it to close in Q4 2021, pending regulatory approvals.
TAMPA, Fla., Oct. 08, 2021 – Pacira BioSciences (NASDAQ: PCRX) announces an Investor Day on October 15, 2021, from 8:00 AM to 12:00 PM ET, at its Innovation and Training Center in Tampa. Key Opinion Leaders and the executive team will discuss updates on the company's commercial products and pipeline opportunities. Attendance is limited and requires advance registration. A live webcast and archived replay will be available on PaciraInvestorDay.com.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has received a Paragraph IV Certification Notice Letter from eVenus Pharmaceutical Laboratories regarding a generic version of EXPAREL (bupivacaine liposome injectable suspension). eVenus alleges the corresponding patent is invalid. Pacira is poised to defend its patent rights and has 45 days to initiate a lawsuit. The company possesses additional patents set to extend EXPAREL's market exclusivity into the 2040s, contributing to its competitive position in non-opioid pain management.